Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection

Wang, Xue; Hui, Tianli; Wang, Meiqi; Liu, Huan; Li, Ruoyang; Song, Zhao-Hui

doi:10.1159/000496548

Cited by 19 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The starting point was the date of operation, and all ended on December 30, 2019. As we reported previously 33 . For patients who died, the date and cause of death were recorded, and all deaths not attributable to breast cancer were censored at the date of death.…”

Section: Methodssupporting

confidence: 72%

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Hui

Shang

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Early reports indicate that metformin, a clinical drug administered to treat type 2 diabetes mellitus (T2DM), was found to be associated with a better prognosis of cancer. The objective of this study was retrospectively analyzed the effect of metformin on the outcomes of Chinese breast cancer patients with T2DM. A total of 3757 primary invasive breast cancer patients who underwent surgery from January 2010 to December 2013 were enrolled. According to the medication treatment, all the patients were divided as non-diabetes group, metformin group and insulin group. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 3553 patients (median follow up of 85 months) and estimated with the Kaplan–Meier method followed by a log-rank test. Multivariate Cox proportional hazards regression model was applied. The results showed that there was a significant survival difference among non-diabetes group, metformin group and insulin group, 5-year DFS was 85.8%, 96.1%, 73.0%, and 5-year OS was 87.3%, 97.1%, 73.3% respectively (P < 0.05). Prognostic analysis showed metformin was significantly associated with better DFS and OS. Our results suggested that metformin may have a good effect on the survival of invasive breast cancer patients with T2DM.

show abstract

Section: Methodssupporting

confidence: 72%

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Hui

Shang

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Yet, independently to menopausal status, obese women achieve poorer clinical outcomes [ 92 ]. Wang et al showed that females above 50 years old with greater Body Mass Index (BMI) are at a greater risk of cancer compared to those with low BMI [ 93 ]. Besides, the researchers observed that greater BMI is associated with more aggressive biological features of tumor including a higher percentage of lymph node metastasis and greater size.…”

Section: Risk Factors Of Breast Cancermentioning

confidence: 99%

Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review

Łukasiewicz

Czeczelewski

Forma

et al. 2021

Cancers

886

405

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50. Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like). The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences.

show abstract

“…Epidemiologically, estrogen receptor-positive breast cancer develops in obese women in the postmenopausal period ( Kolb and Zhang, 2020 ). However, women more than 50 years of age with greater BMI are at higher risk of breast cancer than those with low BMI ( Wang et al, 2019 ). However, it has been reported that people with a higher BMI are at a high risk of tumors with a high percentage and size of lymph node metastasis.…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence

Almansour

2022

Front. Mol. Biosci.

197

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen, progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for more than 15–20% of all breast cancers and is of particular research interest as it is therapeutically challenging mainly because of its low response to therapeutics and highly invasive nature. The non-availability of specific treatment options for TNBC is usually managed by conventional therapy, which often leads to relapse. The focus of this review is to provide up-to-date information related to TNBC epidemiology, risk factors, metastasis, different signaling pathways, and the pathways that can be blocked, immune suppressive cells of the TNBC microenvironment, current and investigation therapies, prognosis, and the role of artificial intelligence in TNBC diagnosis. The data presented in this paper may be helpful for researchers working in the field to obtain general and particular information to advance the understanding of TNBC and provide suitable disease management in the future.

show abstract

Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection

Cited by 19 publications

References 21 publications

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus

Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review

Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence

Contact Info

Product

Resources

About